NVS  Novartis Ag




Consumer Durables


Major Pharmaceuticals

Market Cap.


Vuru Grade


Current Price

+0.33 (+0.44%)

Growth Price

Overvalued by 26.13%

Stability Price

Overvalued by 80.79%

Company Metrics

  • P/E 27.09
  • P/S 3.62
  • P/B 2.48
  • EPS 2.8
  • Cash ROIC 11.30%
  • Cash Ratio 0.16
  • Dividend 2.72 / 3.6%
  • Avg. Vol. 1.62M
  • Shares 2.38B
  • Market Cap. 180.66B

Company Description

Novartis AG, through its subsidiaries, engages in the research, development, manufacture, and marketing of healthcare products worldwide. Its Pharmaceuticals division offers prescription medicines in various therapeutic areas, including cardiovascular and metabolism; oncology; neuroscience and ophthalmics; respiratory; integrated hospital care; and other additional products. The company's Vaccines... more

Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow


Earnings: EPS Decline Expected for Novartis AG (ADR) (NVS)
MoneyMakingArticles - 8 hours ago
Wall Street await Novartis AG (ADR) (NYSE:NVS) to release earnings on October, 25. Analysts forecast earnings per share of $1.19, down exactly $0.08 or 6.30% from 2014's $1.27 EPS.
Pros Don't Lie: Novartis Ag Sponsored (NVS) Shareholder Tower Bridge Advisors ...
Chester News - 14 hours ago
Chardan Capital Markets initiated Novartis AG (ADR) (NYSE:NVS) rating on Tuesday, September 20. Chardan Capital Markets has “Buy” rating and $95.0 price target.
Here's What's Important With The Novartis AG (ADR) (NVS) MS Data
Insider Monkey (blog) - Aug 29, 2016
Novartis AG (ADR) (NYSE:NVS) just put out data from its multiple sclerosis (MS) trial, and it looks as if the company is winning the race to bring a drug to market that offers a solution for patients with secondary progressive MS (SPMS), a severe form ...
Novartis AG (ADR) (NYSE:NVS) Says A Picture Is Worth A Thousand Words - Market Exclusive
Novartis AG (NYSE:NVS) Fights for Survival after Patent Expiration - TCC
Will Novartis AG (ADR) (NVS) Clinch Biosimilar Market by 2020?
TCC - Aug 8, 2016
Novartis AG's (ADR)(NYSE:NVS) biosimilar and generic division, Sandoz is working for the development of novel biosimilars versions of the blockbuster drugs to patch up the revenue loss of its blockbuster drugs' patents.
Will Novartis AG (ADR) (NVS) be Forbidden in Korea after Bribe Charges?
TCC - Aug 16, 2016
Novartis AG (ADR) (NYSE:NVS) is hit by bad news of involvement of its six senior officials under the charges of corruption.
The Biosimilar of Amgen's Enbrel, by Novartis AG (ADR) (NYSE:NVS), has been ...
TCC - Aug 31, 2016
In a latest development, the Food and Drug Administration (FDA) has announced the approval of Novartis AG's (NYSE:NVS) Erelzi, which is a biosimilar version of Amgen's blockbuster drug Enbrel.
Novartis AG (ADR) Enbrel Biosimilar Approved: What's Next for Amgen? - Smаrt Stоck Nеws
Amgen, Inc: How Damaging Will Be Novartis' Enbrel Copy - Bidness ETC
Novartis AG (ADR) 19.3% Potential Upside Now Implied by Chardan Capital Markets
DirectorsTalk Interviews - Oct 11, 2016
Novartis AG (ADR) using SYMBOL/TICKER code NYSE:NVS has had its stock rating noted as 'Reiterated' with the recommendation being set at 'BUY' yesterday by research analysts at Chardan Capital Markets.
Institutional Move From SEC: Quest Investment Management INC Lowered Novartis ...
Chester News - Oct 18, 2016
Quest Investment Management Inc decreased its stake in Novartis A G Sponsored Adr (NVS) by 19.84% based on its latest 2016Q2 regulatory filing with the SEC.
Novartis AG (ADR) (NYSE:NVS) To Pay $25 Million Over Bribery Allegations
Market Exclusive - Mar 25, 2016
Last year GlaxoSmithKline plc (ADR) (NYSE:GSK) posted a 17% drop in sales as a state-led campaign on drug prices affected returns.
Novartis AG (ADR) (NVS) Multiple Sclerosis Molecule: Ray of Hope
TCC - Sep 19, 2016
Novartis AG (ADR) (NYSE:NVS) investigational molecule for the treatment and management of multiple sclerosis has shown remarkable reduction in the disease progression up to 21%.